Fabienne Foster-Witassek

Fabienne Foster-Witassek

Auto-generated profile, based on publicly available information

Fabienne Foster-Witassek

University of Zürich

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 December 2022 in European Journal of Preventive Cardiology
Verified
Journal Article
Closed access
PDF file
FFFabienne Foster-Witassek
Fabienne Foster-Witassek
HRHans Rickli
Hans Rickli
MRMarco Roffi
Marco Roffi
GPGiovanni Pedrazzini
Giovanni Pedrazzini
FEFranz Eberli
Franz Eberli
DRDragana Radovanovic
Dragana Radovanovic
Aims: This study aimed to analyse changes in pre-hospital delay over time in women and men presenting with ST-elevation myocardial infarction (STEMI) in Switzerland. Methods and results: AMIS Plus registry data of patients admitted for STEMI between 2002 and 2019 were analysed using multivariable quantile regression including the following covariates: interaction between sex and admission year, age, diabetes, pain at presentation, myocardial infarction (MI) history, heart failure history, hypertension, and renal disease. Among the 15,350 patients included (74.5% men), the median (interquartile range) delay between 2002 and 2019 was 150 (84; 345) min for men and 180 (100; 414) min for women. The unadjusted median pre-hospital delay significantly decreased over time for both sexes but the decreasing trend was stronger for women. Specifically, the unadjusted sex differences in delay decreased from 60 min in 2002 (P = 0.0042) to 40.5 min in 2019 (P = 0.165). The multivariable model revealed a significant interaction between sex and admission year (P = 0.038) indicating that the decrease in delay was stronger for women (−3.3 min per year) than for men (−1.6 min per year) even after adjustment. The adjusted difference between men and women decreased from 26.93 min in 2002 to −1.97 min for women in 2019. Conclusion: Over two decades, delay between symptom onset and hospital admission in STEMI decreased significantly for men and women. The decline was more pronounced in women, leading to the sex gap disappearing in the adjusted analysis for 2019.

11 June 2024 in Scientific Reports
Verified
Journal Article
Open access
PDF file
FBFabio Barresi
Fabio Barresi
FFFabienne Foster-Witassek
Fabienne Foster-Witassek
HRHans Rickli
Hans Rickli
GPGiovanni Pedrazzini
Giovanni Pedrazzini
MRMarco Roffi
Marco Roffi
DRDragana Radovanovic
Dragana Radovanovic
This study aimed to examine whether acute myocardial infarction (AMI) patients in Switzerland return to work and identify factors associated therewith. Data of 4315 working-age AMI patients enrolled in the Swiss AMIS Plus registry between 01/2006 and 09/2021 with 1-year follow-up and self-reported work status were analyzed. Patient characteristics were compared between those who did not reduce their work hours, those who reduced, and those who were no longer working 1 year after AMI. Multinomial logistic regression was used to analyze independent predictors of working ability. Of the patients, 3204 (74.3%) did not reduce their work hours, 592 (13.7%) reduced and 519 (12.0%) were no longer working 1 year after AMI. Women were more likely to reduce or stop working. Patients who did not reduce were more frequently young and male. Multinomial logistic regression showed that work reduction was associated with female sex and a Killip class > 2 at admission whereas stopping work was associated with female sex and comorbidities. A high rate of AMI patients in Switzerland (88%) return to work 1 year after AMI. Approximately 1 in 8 did not return to work and approximately 1 in 7 reduced their work hours. Important factors associated with reducing or no longer working after AMI were female sex, older age and a higher proportion of comorbidities.

7 November 2023 in Journal of the American Heart Association
Verified
Journal Article
Open access
FFFabienne Foster‐Witassek
Fabienne Foster‐Witassek
HAHelena Aebersold
Helena Aebersold
SAStefanie Aeschbacher
Stefanie Aeschbacher
PAPeter Ammann
Peter Ammann
JBJuerg beer
Juerg beer
TIthe Swiss‐AF Investigators
the Swiss‐AF Investigators
Background: Optimizing health‐related quality of life (HRQoL) is an important aim of atrial fibrillation (AF) treatment. Little is known about patients' long‐term HRQoL trajectories and the impact of patient and disease characteristics. The aim of this study was to describe HRQoL trajectories in an observational AF study population and in clusters of patients with similar patient and disease characteristics. Methods and Results: We used 5‐year follow‐up data from the Swiss–Atrial Fibrillation prospective cohort, which enrolled 2415 patients with prevalent AF from 2014 to 2017. HRQoL data, collected yearly, comprised EuroQoL‐5 dimension utilities and EuroQoL visual analog scale scores. Patient clusters with similar characteristics at enrollment were identified using hierarchical clustering. HRQoL trajectories were analyzed descriptively and with inverse probability‐weighted regressions. Effects of postbaseline clinical events were additionally assessed using time‐shifted event variables. Among 2412 (99.9%) patients with available baseline HRQoL, 3 clusters of patients with AF were identified, which we characterized as follows: “cardiovascular dominated,” “isolated symptomatic,” and “severely morbid without cardiovascular disease.” Utilities and EuroQoL visual analog scale scores remained stable over time for the full population and the clusters; isolated symptomatic patients showed higher levels of HRQoL. Utilities were reduced after occurrences of stroke, hospitalization for heart failure, and bleeding, by −0.12 (95% CI, −0.18 to −0.06), −0.10 (95% CI, −0.13 to −0.08), and −0.06 (95% CI, −0.08 to −0.04), respectively, on a 0 to 1 utility scale. Utility of surviving patients returned to preevent levels 4 years after heart failure hospitalization; 3 years after bleeding; and 1 year after stroke. Conclusions: In patients with prevalent AF, HRQoL was stable over time, irrespective of baseline patient characteristics. Clinical events of hospitalization for heart failure, stroke, and bleeding had only a temporary effect on HRQoL.

12 August 2025 in European Heart Journal - Cardiovascular Pharmacotherapy
Verified
Journal Article
Open access
MMMicha Maeder
Micha Maeder
FFFabienne Foster-Witassek
Fabienne Foster-Witassek
DRDragana Radovanovic
Dragana Radovanovic
MRMarco Roffi
Marco Roffi
GPGiovanni Pedrazzini
Giovanni Pedrazzini
HRHans Rickli
Hans Rickli
Aims: While the beneficial effect of beta-blocker (BB) therapy for acute coronary syndrome (ACS) patients with a left ventricular ejection fraction (LVEF) of 40% is established, its role in those with LVEF > 40% is controversial. We assessed the relationship between BB therapy at discharge and 1-year mortality according to LVEF in a large contemporary acute coronary syndrome (ACS) cohort. Methods and results: Patients enrolled in the Acute Myocardial Infarction in Switzerland (AMIS) Plus registry between 2005 and 2024 with information on BB at discharge, LVEF, and 1-year mortality were studied. The association between BB therapy and 1-year mortality and the interaction with LVEF (>40% vs. ≤40%) were analysed. Among 7820 patients (65% with ST-segment elevation myocardial infarction), 1570 (20.1%) had LVEF ≤ 40%. At discharge, 6211/7820 (79.4%) patients were on BB (LVEF > 40%, 78.1%; LVEF ≤ 40%, 84.5%). One-year mortality was higher in patients with LVEF ≤ 40% vs. >40% (7.1% vs. 2.3%; P < 0.001). Overall, BB therapy was associated with reduced mortality [unadjusted odds ratio 0.67 (95% confidence interval 0.51–0.89); P = 0.005]. Among patients with LVEF ≤ 40%, mortality was lower in patients with BB compared with those without (5.9% vs. 14%; P < 0.001). In contrast, in patients with LVEF > 40%, mortality did not differ between patients with and without BB (2.1% vs. 2.6%; P = 0.3). A statistically significant interaction between BB therapy and LVEF stratum was identified (pinteraction = 0.02). Conclusion: Data from our large, nationwide registry suggest an overall benefit of BB therapy at discharge on 1-year mortality in ACS with most of the survival advantage observed in patients with LVEF < 40%.

19 September 2025 in European Heart Journal: Acute Cardiovascular Care
Verified
Journal Article
Closed access
NONicola Olivito
Nicola Olivito
FWFabienne Foster Witassek
Fabienne Foster Witassek
HRHans Rickli
Hans Rickli
MRMarco Roffi
Marco Roffi
DRDragana Radovanovic
Dragana Radovanovic
GPGiovanni Pedrazzini
Giovanni Pedrazzini
Aims: Contemporary data on the impact of high-grade atrioventricular blocks (HAVB) in acute myocardial infarction (AMI) are scarce. Therefore, we investigated this in the Swiss national AMI registry (AMIS Plus) cohort. Methods and results: We included all AMI patients enrolled from January 2005 to September 2024 with available ECG information. Primary outcome was in-hospital mortality; secondary outcomes included in-hospital major adverse cardiac or cerebrovascular events (MACCE) defined as cardiogenic shock, stroke, re-infarction or death. Among 50 279 AMI patients, 747 (1.5%) patients presented with HAVB and 407 (0.8%) developed HAVB during hospitalization. Patients presenting with HAVB had increased in-hospital mortality (15% vs. 4.9%; P < 0.001) and MACCE (17% vs. 6.0%; P < 0.001) compared with those without HAVB. High-grade atrioventricular blocks on admission was an independent predictor for in-hospital mortality (OR 1.89; 95% CI, 1.42–2.49; P < 0.001), with a stronger impact on mortality in the setting of anterior compared to non-anterior AMI (OR 3.69; 95% CI, 1.99–6.81; pinteraction = 0.02). Independent predictors for HAVB on admission included STEMI and female sex. Rates of permanent pacemaker implantation during hospitalization in patients with HAVB on admission were higher in NSTEMI than STEMI patients (20% vs. 4.4%; P < 0.001). High-grade atrioventricular blocks occurring during hospital stay was associated with higher mortality (20% vs. 15%; P = 0.031) and higher permanent pacemaker rate (25% vs. 8%; P < 0.001) than HAVB on admission. Conclusion: High-grade atrioventricular blocks in AMI was associated with high in-hospital mortality, especially in anterior AMI or if occurring during hospitalization. Permanent pacemaker implantation was more frequent in the setting of NSTEMI and among patients developing HAVB during hospital stay.

1 January 2025 in Swiss Medical Weekly
Verified
Journal Article
Open access
PDF file
HAHelena Aebersold
Helena Aebersold
FFFabienne Foster-Witassek
Fabienne Foster-Witassek
SASina Amberg
Sina Amberg
MSMiquel Serra-Burriel
Miquel Serra-Burriel
GMGeorgios A. Moschovitis
Georgios A. Moschovitis
MSMatthias Schwenkglenks
Matthias Schwenkglenks
AIMS: We aimed to explore atrial fibrillation (AF)-induced productivity losses in working-age atrial fibrillation patients and to estimate atrial fibrillation-related indirect costs. METHODS: Between 2014 and 2017, the Swiss Atrial Fibrillation prospective cohort study (Swiss-AF) enrolled 217 working-age patients with documented atrial fibrillation. Self-reported changes in professional activity and the reasons thereof were descriptively analysed over 8 years of follow-up or until patients reached the retirement age. Results were put into perspective, and indirect costs were planned to be estimated, through comparison with a general population-based, age-, sex- and year-matched comparison sample from the Swiss labour force survey (SLFS). RESULTS: Of 217 analysed Swiss-AF patients, 14.7% reported a professional activity change (9.2% stop, 5.5% reduction) due to atrial fibrillation before the end of observation. Of those working at enrolment (n = 157), 3.8% had a subsequent professional activity change due to atrial fibrillation, 11.6% due to other reasons. Patients were more likely to report an impact of atrial fibrillation on professional activity if they had had atrial fibrillation longer and were closer to the retirement age. Slightly fewer Swiss-AF patients were employed (75%) than in the comparison sample (77%). For those working however, the degree of employment was higher (88% vs 83%). Lack of differences between the Swiss-AF patients and the comparison sample indicated no relevant indirect costs of atrial fibrillation due to lost productivity. CONCLUSION: Only a minority of atrial fibrillation patients reported a negative impact of atrial fibrillation on their professional activity. Professional activity changes due to other reasons were reported more frequently. Compared with the general population, atrial fibrillation did not cause distinct differences.